Distal pancreatectomy with celiac axis resection for locally advanced pancreatic carcinoma: case report

Pancreatectomia distal com ressecção do eixo celíaco para carcinoma pancreático localmente avançado: relato de caso

Renato Morato Zanatto 1, Patrícia Medeiros Milhomem Beato2, Maurício José Vieira3, Celso Roberto Passeri1

ABSTRACT

Long-term survival of pancreatic ductal adenocarcinoma after surgery is still rare. One of the main reasons for unresectability is the tumor invasion of the main vessels, such as the celiac axis, common hepatic artery and superior mesenteric artery. The optimal management of these patients is controversial. Despite the challenges on the topic, we present a case of pancreatic ductal adenocarcinoma with invasion of the celiac axis treated with pancreatectomy and vascular resection plus perioperative chemoradiotherapy. After 30 months of follow-up, hepatic and peritoneal recurrence were identified. Palliative chemotherapy was administered until disease progression and death in March 2020. Surgical resection when used in selected patients, proved to be feasible with acceptable morbidity. Besides that, the aggressive surgical approach associated with multimodal schemes provided an improvement in disease-free and overall survival.

Keywords: Neoadjuvant therapy; Pancreatic neoplasms; Surgery.
RESUMO
A sobrevida a longo prazo do adenocarcinoma ductal pancreático após a cirurgia ainda é rara. Um dos principais motivos da irressecabilidade é a invasão tumoral dos principais vasos, como o eixo celiaco, a artéria hepática comum e a artéria mesentérica superior. O manejo ideal desses pacientes é controverso. Apesar dos desafios no assunto, apresentamos um caso de adenocarcinoma ductal pancreático com invasão do eixo celiaco tratado com pancreatectomia e ressecção vascular associada à quimiorradiooterapia perioperatória. Após 30 meses de acompanhamento, foram identificadas recidivas hepática e peritoneal. A quimioterapia paliativa foi administrada até a progressão da doença e óbito em março de 2020. A ressecção cirúrgica, quando utilizada em pacientes selecionados, mostrou-se viável com morbididade aceitável. Além disso, a abordagem cirúrgica agressiva associada a esquemas multimodais proporcionou melhora na sobrevida livre de doença e global.

Descritores: Terapia neoadjuvante; Neoplasias pancreáticas; Cirurgia.

INTRODUCTION
Approximately 57,600 people develop exocrine pancreatic cancer each year in the United States and more than 90% of them are expected to die from their disease. The most common histological type is pancreatic ductal adenocarcinoma (PDAC), responsible for more than 85% of cases. Surgical resection is the only potentially curative treatment. Unfortunately, due to the late presentation of the disease, only 15 to 20% of patients are candidates for pancreatectomy. Vascular involvement is related to the low rates of resectability observed in the disease, but its relationship with the prognosis is controversial. Resection of the portal vein (PV) and superior mesenteric vein (SMV) combined with pancreatectomy is a safe and viable procedure, which may increase the number of patients undergoing potentially curative resection and, therefore, provides important survival benefits for selected cases. On the other hand, few data in the literature are available to support arterial resection in PDAC. Surgical treatment in these cases is infrequent and when performed, it is related to an increase in morbidity and mortality.

Currently, chemotherapy has been the initial treatment with locally advanced or unresectable PDAC. The approach aims to “shrink the tumor volume” before surgical exploration using chemotherapy with or without RT. As demonstrated in ESPAC-5F, a prospective, multicenter international phase II randomized four-arm clinical trial that compared immediate surgery with gemcitabine neoadjuvant plus capcitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in PDAC with borderline resectable disease. The results demonstrated the one-year survival rate was 40% [95% CI, 26%-62%] for immediate surgery and 77% [95% CI, 66%-89%] for neoadjuvant therapy. Regarding to the addition of RT in the neoadjuvant treatment, unfortunately, it is not known whether it contributes to the R0 resection rate in patients treated with aggressive combination regimens, such as FOLFIRINOX.

We present a case of PDAC with invasion of the celiac axis (CA) treated with surgical resection after proven disease stability with neoadjuvant chemotherapy, despite the controversies and challenges on the subject.

CASE REPORT
A 42-year-old, female, previously healthy patient presented with low back pain on the right and 7kg weight loss for 4 months. Contrast-enhanced CT showed a nodule in the body of the pancreas 2.6x2.4cm involving the bifurcation of the celiac axis. Anatomical variations were not observed (Figure 1) and CA 19-9 was in 130. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) evidenced nodule of the pancreas body of 3.2x3.0cm and the involvement of the splenic artery emergence near the celiac trunk with histopathologic findings adenocarcinoma. PET scan showed the nodule of the pancreas body with SUV 5.8 (Figure 2).

RESUMO
A sobrevida a longo prazo do adenocarcinoma ductal pancreático após a cirurgia ainda é rara. Um dos principais motivos da irressecabilidade é a invasão tumoral dos principais vasos, como o eixo celiaco, a artéria hepática comum e a artéria mesentérica superior. O manejo ideal desses pacientes é controverso. Apesar dos desafios no assunto, apresentamos um caso de adenocarcinoma ductal pancreático com invasão do eixo celiaco tratado com pancreatectomia e ressecção vascular associada à quimiorradiooterapia perioperatória. Após 30 meses de acompanhamento, foram identificadas recidivas hepática e peritoneal. A quimioterapia paliativa foi administrada até a progressão da doença e óbito em março de 2020. A ressecção cirúrgica, quando utilizada em pacientes selecionados, mostrou-se viável com morbididade aceitável. Além disso, a abordagem cirúrgica agressiva associada a esquemas multimodais proporcionou melhora na sobrevida livre de doença e global.

Descritores: Terapia neoadjuvante; Neoplasias pancreáticas; Cirurgia.
After multidisciplinary discussion, we decided to start treatment for this clinical staging III-cT4N0M0 patient, with chemotherapy consisting of 3 cycles of the FOLFIRINOX regimen. In her tumor access after chemoradiation, the patient was classified by the RECIST 1.1 method as a stable disease.

Surgical exploration was carried out on September 2016, it took place without complications for duration of 240 min and without the need for blood transfusion. Preoperative preparation included a vaccine against encapsulated germs. After complete the dissection and repair the vascular structures, surgery included a block resection of the body and tail of the pancreas, celiac axis and branches, spleen and stomach (Roux-en-Y reconstruction). Primary anastomosis of common hepatic artery (CHA) with CA was made and suture of the stump and pancreatic duct (Figure 3). Histological work-up revealed R0 resection, PDAC, G2, and ypT4N1Mx.

The patient's clinical course was uneventful, only transient alteration of liver functions, remaining in the intensive care unit for 48 hours and being discharged on the 9th postoperative day. It evolves without pancreatic fistula but with weight loss and difficult to control diarrhea managed with pancreatic enzyme replacement and nutritional support. Received adjuvant CRT (gemcitabine plus RT) due to the high-risk of developing metastases.

After 30 months of oncological follow-up, the patient evolved with an elevation of CA19.9 - 3000. Restaging tests and EUS-FNA biopsy showed hepatic and peritoneal recurrence. FOLFIRINOX in an adjusted dose was administered until disease progression followed by sequential treatments of gemcitabine and capecitabine managed through disease progression and death on March 2020.

**DISCUSSION**

Long-term survival of PDAC after surgery is still rare. One of the main reasons for unresectability is the tumor involvement of the main vessels, such as the CA, CHA, and SMA. The optimal management of these patients is controversial, and there is no standard approach.

The aim of the staging workup is to delineate the extent of disease spread and identify patients who are eligible for resection or preoperative treatment. Imaging exams should analyzed with special attention to vascular variations of the CHA, because, when not detected, may represent a risk of accidental iatrogenic injury in vessels with consequent hepatic infarction. An initial assessment of resectability can usually be made based upon the CT scan or magnetic resonance imaging (MRI). The utility of positron emission tomography (PET) scans in the staging of suspected PDAC remains controversial.

The lack of staging laparoscopy did not compromise the outcome of the treatment of this case. However, based on current data, this approach should be used with occult metastases identified in 29% of patients with resectable tumor on CT scan.

EUS-FNA or CT-guided percutaneous core needle biopsy (CT-CNB) is mandatory and provide histologic diagnostic before neoadjuvant therapy, as well an assessment of the serum levels of CA 19-9. This approach increase the amount of patients becoming eligible for surgery, avoiding unnecessary operations on tumors with aggressive biology that evolve despite neoadjuvant therapy.

Tumors with limited venous involvement, resection of the portal vein (PV), and superior mesenteric vein (SMV) combined with pancreatectomy provide an increase in the number of patients undergoing potentially curative resection and, therefore, important survival benefits for selected cases. On the other hand, unresectable PDAC with arterial involvement, resections are performed infrequently, with most of tumors treated non-surgically with chemotherapy or chemoradiation associated with radiotherapy (CRT).

The 5-year overall survival (OS) for metastatic PDAC remains at 2%, with a median life expectancy of <1 year with current treatments. In our report, the patient underwent pancreatectomy with vascular resection of CA after neoadjuvant therapy. Received adjuvant CRT (gemcitabine plus RT) due to the high risk of developing metastases. Concerning, hepatic artery reconstruction, albeit postoperative liver infarction is unusual, it is a potentially deadly complication. There are some reports standing the use of
Distal pancreatectomy with celiac artery embolization or hepatic common artery ligation by laparoscopy to promote development of collateral pathways prior to pancreatectomy with hepatic artery resection. Due to this specific approach, hepatic artery reconstruction could be avoided in previous accessed cases.

In our report, after perform a primary anastomosis of CHA with CA, a total gastric resection was the option founded to remediate fund gastric ischemia, arising from splenic and left gastric artery ligation. The right gastroepiploic arcade was not enough to provide fund gastric irrigation and the patient did not have a distal left gastric artery stump with matching gauge to allow anastomosis without microsurgery.

CONCLUSION

Although complex, pancreatectomy with vascular resection proved to be viable with acceptable morbidity in our service. The OS achieved in our report was 42 months. To maximize the result, it was mandatory a careful selection of the patient, neoadjuvant chemotherapy, and adequate radiological evaluation.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. DOI: https://doi.org/10.3322/caac.21590
2. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talambot MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007 Aug;246(2):173-80. DOI: https://doi.org/10.1097/SLA.0b013e3180691579
3. Sanjay P, Takaori K, Govil S, Shrikhande SV, Windom JA. ‘Artery-first’ approaches to pancreateoduodenectomy. Br J Surg. 2012 Aug;99(8):1027-35. DOI: https://doi.org/10.1002/bjs.8763
4. Tseng JF, Raut CP, Lee JE, Pisters PWT, Vauthey JN, Abdalla EK, et al. Pancreatectoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004 Dec;8(8):935-50. DOI: https://doi.org/10.1016/j.gassur.2004.09.046
5. Gurusamy KS, Kumar S, Davidson BR, Fusai G. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014 Feb;2:CD010244.
6. Yamada S, Fujii T, Sugimoto H, Shuji N, Shin T, Yasuhiro K, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013 Aug;42(6):1004-10. DOI: https://doi.org/10.1097/MPA.0b013e31827b2d7c
7. Sohal D, Duong MT, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, et al. SWOG S1505: results of perioperative chemotherapy (peri-op CTx) with mFOLFOX6 versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2020;38(Suppl 15):4504.
8. Hidalgo M. Pancreatic cancer pancreatic cancer: overview. N Engl J Med. 2011 Aug;362:1605-17.
9. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreatectoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15(3):928-37. DOI: https://doi.org/10.1200/JCO.1997.15.3.928
10. Hackert T, Sashenmaier M, Hinz U, Schneider L, Michalski CW, Springfield C, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016 Sep;264(3):457-61.
11. Kelemen D, Löcsei Z, Papp R, Ferenicz S, Vereczkei A. Appleby procedure - an option for surgical treatment of pancreatic body tumour infiltrating the celiac axis. Magy Seb. 2018 Mar;71(1):16-20. DOI: https://doi.org/10.1556/1046.71.2018.1.3
12. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical practice guideline. J Clin Oncol. 2016 Jul;34(21):2541-56.
13. Kensi Y, Yamashita YI, Yamao T, Kuroda D, Eto T, Kitano Y, et al. Efficacy of staging laparoscopy for pancreatic cancer. Anticancer Res. 2020 Feb;40(2):1023-7. DOI: https://doi.org/10.21873/anticancer.14037
14. Takadate T, Morikawa T, Ishida M, Aoki S, Hata T, Iseki M, et al. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Surg Today. 2020 Sep;51(1):686-94. DOI: https://doi.org/10.1007/s00595-020-02121-4
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar/Apr;56(2):106-30.
16. American Cancer Society (ACS). Cancer facts and Statistics - Figures 2013 [Internet]. Atlanta: ACS; 2013; [access in ANO Mês dia]. Available from: www.cancer.org/research/cancerfactsfigures/cancer-factsfigures/cancer-facts-figures-2013
17. Malvezzi M, Bertucchio P, Levi F, Vechia CL, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013 Mar;24(3):792-800.
18. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzesse JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol. 2000 Jan;95(1):17-31.
19. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May;364:1817-25.
20.Raut V, Takaori K, Kawaguchi Y, Mizumoto M, Kawa guchi M, Koizumi M, et al. Laparoscopic common hepatic artery ligation and stageing followed by distal pancreatectomy with en bloc resection of celiac artery for advanced pancreatic cancer.” Asian J Endosc Surg. 2011 Nov;4(4):199-202. DOI: https://doi.org/10.1111/j.1758-5910.2011.00105
21. Sato T, Inoue Y, Takahashi Y, Mise Y, Ishizawa T, Iseki M, et al. Efficacy of staging laparoscopy for pancreatic cancer. Anticancer Res. 2020 Feb;40(2):1207-17. DOI: https://doi.org/10.21873/anticancer.14037